相关实验视频

Updated: Sep 14, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

TLR4/MyD88表达模式和新型遗传变异:与结直肠癌中具有侵略性临床病理特征的关联

Thai Tra Dang^1,2, Viet Nhat Pham³, Ngoc Dung Tran¹

¹Department of Pathology and Forensic Medicine, Military Hospital 103, Vietnam Military Medical University, Hanoi, Vietnam.

Frontiers in oncology

|July 24, 2025

概括

收费类受体4 (TLR4) 和骨髓分化因子88 (MyD88) 信号传递在结直肠癌 (CRC) 中至关重要. 在TLR4和MyD88中的新型遗传变异与CRC风险增加和瘤特征的攻击性有关,提供潜在的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

收费类受体4 (TLR4) 和骨髓分化因子88 (MyD88) 信号传递与结直肠癌 (CRC) 的发展有关.
在CRC进展过程中,从腺瘤到癌瘤,遗传变异和蛋白质表达之间的相互作用尚未完全理解.

研究的目的:

在结直肠癌进展过程中调查TLR4和MyD88的表达模式.
确定TLR4和MyD88中的遗传变异,并评估它们与CRC风险和临床病理特征的关联.

主要方法:

一项涉及176名CRC患者和131名腺瘤患者的横截面研究.
免疫组织化学被用来评估TLR4和MyD88蛋白质表达.
DNA测序确定了遗传变异,多变量分析评估了与临床病理特征的关联.

主要成果:

在CRC中,TLR4的表达显著高于腺瘤 (66.5%与30.5%,p<0.001).
在TLR4 (9:117713042) 和MyD88 (rs138284536) 新型变异与CRC风险增加有关 (OR=8.92,p=0.037和OR=20.01,p<0.001,分别).
这种MyD88变异与具有攻击性特征相关,包括粘膜组织学,晚期PT阶段和围神经入侵. 结合的TLR4/MyD88得分预测了淋巴结转移和高度瘤芽.

结论:

独特的TLR4/MyD88表达模式和新的遗传变异与CRC进展和侵袭性瘤特征有关.
这些分子变化可以作为CRC风险分层和预后评估的潜在生物标志物.
已识别的途径和变体代表了结直肠癌治疗干预的有希望的目标.

关键词:

通过TLR4/MyD88路径.临床病理学特征临床病理学特征结肠直肠癌的发生遗传多形态的遗传多形态.微卫星的不稳定性分子生物标志物分子生物标志物

更多相关视频

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...